Cyclerion Therapeutics Stock Probability of Future Stock Price Finishing Under 2.79
| CYCN Stock | USD 2.75 0.18 6.14% |
Cyclerion |
Cyclerion Therapeutics Target Price Odds to finish below 2.79
The tendency of Cyclerion Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 2.79 after 90 days |
| 2.75 | 90 days | 2.79 | about 38.78 |
Based on a normal probability distribution, the odds of Cyclerion Therapeutics to stay under $ 2.79 after 90 days from now is about 38.78 (This Cyclerion Therapeutics probability density function shows the probability of Cyclerion Stock to fall within a particular range of prices over 90 days) . Probability of Cyclerion Therapeutics price to stay between its current price of $ 2.75 and $ 2.79 at the end of the 90-day period is under 4.
Given the investment horizon of 90 days the stock has the beta coefficient of 2.32 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Cyclerion Therapeutics will likely underperform. Additionally Cyclerion Therapeutics has an alpha of 0.6658, implying that it can generate a 0.67 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Cyclerion Therapeutics Price Density |
| Price |
Predictive Modules for Cyclerion Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cyclerion Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cyclerion Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cyclerion Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cyclerion Therapeutics is not an exception. The market had few large corrections towards the Cyclerion Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cyclerion Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cyclerion Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.67 | |
β | Beta against Dow Jones | 2.32 | |
σ | Overall volatility | 0.39 | |
Ir | Information ratio | 0.07 |
Cyclerion Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cyclerion Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cyclerion Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cyclerion Therapeutics is way too risky over 90 days horizon | |
| Cyclerion Therapeutics appears to be risky and price may revert if volatility continues | |
| Cyclerion Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.26 M) with loss before overhead, payroll, taxes, and interest of (29.75 M). | |
| Cyclerion Therapeutics currently holds about 30.32 M in cash with (21.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7. | |
| Cyclerion Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 14760 shares by Cheryl Gault of Cyclerion Therapeutics at 16.02 subject to Rule 16b-3 |
Cyclerion Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cyclerion Stock often depends not only on the future outlook of the current and potential Cyclerion Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cyclerion Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.3 M | |
| Cash And Short Term Investments | 7.6 M |
Cyclerion Therapeutics Technical Analysis
Cyclerion Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Cyclerion Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cyclerion Therapeutics. In general, you should focus on analyzing Cyclerion Stock price patterns and their correlations with different microeconomic environments and drivers.
Cyclerion Therapeutics Predictive Forecast Models
Cyclerion Therapeutics' time-series forecasting models is one of many Cyclerion Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cyclerion Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Cyclerion Therapeutics
Checking the ongoing alerts about Cyclerion Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cyclerion Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Cyclerion Therapeutics is way too risky over 90 days horizon | |
| Cyclerion Therapeutics appears to be risky and price may revert if volatility continues | |
| Cyclerion Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.26 M) with loss before overhead, payroll, taxes, and interest of (29.75 M). | |
| Cyclerion Therapeutics currently holds about 30.32 M in cash with (21.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7. | |
| Cyclerion Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 14760 shares by Cheryl Gault of Cyclerion Therapeutics at 16.02 subject to Rule 16b-3 |
Additional Information and Resources on Investing in Cyclerion Stock
When determining whether Cyclerion Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclerion Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclerion Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclerion Therapeutics Stock:Check out Cyclerion Therapeutics Backtesting, Cyclerion Therapeutics Valuation, Cyclerion Therapeutics Correlation, Cyclerion Therapeutics Hype Analysis, Cyclerion Therapeutics Volatility, Cyclerion Therapeutics History as well as Cyclerion Therapeutics Performance. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.